Corticosteroid: adverse event reports filed with FDA

808,789

reports across the class

3.9% of all reports

62,248

reports, 12 months to June 2026

73,086 in the 12 months before

77.7%

marked serious by the reporter

57.4% across all reports

74

drugs with a page

brand and generic names counted separately

Drugs in the class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

1. Drug ineffectivethe medicine did not work as expected15%121,620
2. Off label useused for a purpose or in a way not on the label11.4%92,032
3. Dyspnoeashortness of breath9.2%74,051
4. Fatiguetiredness6.9%55,765
5. Painpain, site not specified6.6%53,147
6. Asthmaasthma5.9%48,061
7. Condition aggravatedthe condition being treated got worse5.6%45,277
8. Rashskin rash5.3%42,555
9. Pneumonialung infection5.1%41,149
10. Pyrexiafever4.9%39,702
11. Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease4.9%39,395
12. Headachehead pain4.7%38,317
13. Wheezingwheezing4.6%37,374
14. Product use in unapproved indicationused for a purpose not on the label4.5%36,184
15. Nauseafeeling sick4.4%35,489
16. Abdominal discomfortstomach discomfort4.3%35,177
17. Alopeciahair loss4.3%35,084
18. Systemic lupus erythematosuslupus, an autoimmune disease4.3%34,886
19. Hypersensitivityan allergic-type reaction4.2%34,247
20. Arthralgiajoint pain4.1%33,418
21. Drug intolerancethe medicine was not tolerated4.1%33,236
22. Diarrhoealoose or frequent stools4.1%32,871
23. Infusion related reactiona reaction during or soon after an infusion4.1%32,786
24. Swellingswelling4%32,349
25. Pemphigus4%32,259

Solid bar: share of all class reports. Hollow bar: the median share across the 74 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.